Radioimmunotherapy with an antibody to HPV16 E6 oncoprotein is effective in experimental cervical tumor expressing low levels of E6

Rébécca Phaeton, Matthew Harris, Zewei Jiang, Xing Guo Wang, Mark H. Einstein, Gary L. Goldberg, Arturo Casadevall, Ekaterina Dadachova

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Purpose: HPV16 is associated with ∼50% of all cervical cancers worldwide. The E6 and E7 genes of oncogenic HPV types, such as HPV16, are necessary for the HPV transforming function and tumorogenesis making them ideal targets for novel treatments. Radioimmunotherapy employs systemically administered radiolabeled monoclonal antibodies (mAbs) that bind to tumor-associated antigens. Previously we demonstrated in mice that radioimmunotherapy targeting viral antigens with mAb to HPV16 E6 suppressed CasKi cervical tumors expressing high levels of E6 (∼600 copies of HPV per cell). However, that study opened the question whether radioimmunotherapy can suppress the growth of cervical tumors with low E6 and E7 expression, such as may be seen in patients. Experimental Design: We evaluated the expression of E6 in patients' tumors and in the siHa cell line expressing low levels of E6 and E7 (1-2 copies of HPV per cell) and found them comparable. We initiated siHa tumors in nude mice, radiolabeled C1P5 mAb to E6 with a beta-emitter 188-Rhenium (188Re) and treated tumor-bearing mice with: (1) 200 μCi 188Re-C1P5 alone; (2) proteasome inhibitor MG132 alone; (3) MG132 followed by 200 μCi 188Re-C1P5; (4) unlabeled C1P5; (5) 200 μCi 188Re-18B7 (isotype-matching control mAb); (6) no treatment. 188Re-C1P5 alone and in combination with MG-132 significantly retarded tumor growth compared to all control groups. Conclusions: Our data demonstrate the possibility to suppress tumor growth by targeting viral antigens even in cervical tumors with low E6 expression and provide additional evidence for the potential usefulness of radioimmunotherapy targeting HPV-related antigens in the clinic.

Original languageEnglish (US)
Pages (from-to)1041-1047
Number of pages7
JournalCancer Biology and Therapy
Volume10
Issue number10
DOIs
StatePublished - Nov 15 2010

Fingerprint

Radioimmunotherapy
Oncogene Proteins
Rhenium
Antibodies
Neoplasms
Viral Antigens
Growth
Proteasome Inhibitors
Neoplasm Antigens
Nude Mice
Uterine Cervical Neoplasms
Research Design
Monoclonal Antibodies
Antigens
Cell Line
Control Groups

Keywords

  • 188-rhenium
  • Cervical cancer
  • E6 oncoprotein
  • Radioimmunotherapy
  • Viral antigens

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Molecular Medicine
  • Pharmacology

Cite this

Phaeton, R., Harris, M., Jiang, Z., Wang, X. G., Einstein, M. H., Goldberg, G. L., ... Dadachova, E. (2010). Radioimmunotherapy with an antibody to HPV16 E6 oncoprotein is effective in experimental cervical tumor expressing low levels of E6. Cancer Biology and Therapy, 10(10), 1041-1047. https://doi.org/10.4161/cbt.10.10.13322

Radioimmunotherapy with an antibody to HPV16 E6 oncoprotein is effective in experimental cervical tumor expressing low levels of E6. / Phaeton, Rébécca; Harris, Matthew; Jiang, Zewei; Wang, Xing Guo; Einstein, Mark H.; Goldberg, Gary L.; Casadevall, Arturo; Dadachova, Ekaterina.

In: Cancer Biology and Therapy, Vol. 10, No. 10, 15.11.2010, p. 1041-1047.

Research output: Contribution to journalArticle

Phaeton, R, Harris, M, Jiang, Z, Wang, XG, Einstein, MH, Goldberg, GL, Casadevall, A & Dadachova, E 2010, 'Radioimmunotherapy with an antibody to HPV16 E6 oncoprotein is effective in experimental cervical tumor expressing low levels of E6', Cancer Biology and Therapy, vol. 10, no. 10, pp. 1041-1047. https://doi.org/10.4161/cbt.10.10.13322
Phaeton, Rébécca ; Harris, Matthew ; Jiang, Zewei ; Wang, Xing Guo ; Einstein, Mark H. ; Goldberg, Gary L. ; Casadevall, Arturo ; Dadachova, Ekaterina. / Radioimmunotherapy with an antibody to HPV16 E6 oncoprotein is effective in experimental cervical tumor expressing low levels of E6. In: Cancer Biology and Therapy. 2010 ; Vol. 10, No. 10. pp. 1041-1047.
@article{a04d355e7036404488bc773f60631330,
title = "Radioimmunotherapy with an antibody to HPV16 E6 oncoprotein is effective in experimental cervical tumor expressing low levels of E6",
abstract = "Purpose: HPV16 is associated with ∼50{\%} of all cervical cancers worldwide. The E6 and E7 genes of oncogenic HPV types, such as HPV16, are necessary for the HPV transforming function and tumorogenesis making them ideal targets for novel treatments. Radioimmunotherapy employs systemically administered radiolabeled monoclonal antibodies (mAbs) that bind to tumor-associated antigens. Previously we demonstrated in mice that radioimmunotherapy targeting viral antigens with mAb to HPV16 E6 suppressed CasKi cervical tumors expressing high levels of E6 (∼600 copies of HPV per cell). However, that study opened the question whether radioimmunotherapy can suppress the growth of cervical tumors with low E6 and E7 expression, such as may be seen in patients. Experimental Design: We evaluated the expression of E6 in patients' tumors and in the siHa cell line expressing low levels of E6 and E7 (1-2 copies of HPV per cell) and found them comparable. We initiated siHa tumors in nude mice, radiolabeled C1P5 mAb to E6 with a beta-emitter 188-Rhenium (188Re) and treated tumor-bearing mice with: (1) 200 μCi 188Re-C1P5 alone; (2) proteasome inhibitor MG132 alone; (3) MG132 followed by 200 μCi 188Re-C1P5; (4) unlabeled C1P5; (5) 200 μCi 188Re-18B7 (isotype-matching control mAb); (6) no treatment. 188Re-C1P5 alone and in combination with MG-132 significantly retarded tumor growth compared to all control groups. Conclusions: Our data demonstrate the possibility to suppress tumor growth by targeting viral antigens even in cervical tumors with low E6 expression and provide additional evidence for the potential usefulness of radioimmunotherapy targeting HPV-related antigens in the clinic.",
keywords = "188-rhenium, Cervical cancer, E6 oncoprotein, Radioimmunotherapy, Viral antigens",
author = "R{\'e}b{\'e}cca Phaeton and Matthew Harris and Zewei Jiang and Wang, {Xing Guo} and Einstein, {Mark H.} and Goldberg, {Gary L.} and Arturo Casadevall and Ekaterina Dadachova",
year = "2010",
month = "11",
day = "15",
doi = "10.4161/cbt.10.10.13322",
language = "English (US)",
volume = "10",
pages = "1041--1047",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "10",

}

TY - JOUR

T1 - Radioimmunotherapy with an antibody to HPV16 E6 oncoprotein is effective in experimental cervical tumor expressing low levels of E6

AU - Phaeton, Rébécca

AU - Harris, Matthew

AU - Jiang, Zewei

AU - Wang, Xing Guo

AU - Einstein, Mark H.

AU - Goldberg, Gary L.

AU - Casadevall, Arturo

AU - Dadachova, Ekaterina

PY - 2010/11/15

Y1 - 2010/11/15

N2 - Purpose: HPV16 is associated with ∼50% of all cervical cancers worldwide. The E6 and E7 genes of oncogenic HPV types, such as HPV16, are necessary for the HPV transforming function and tumorogenesis making them ideal targets for novel treatments. Radioimmunotherapy employs systemically administered radiolabeled monoclonal antibodies (mAbs) that bind to tumor-associated antigens. Previously we demonstrated in mice that radioimmunotherapy targeting viral antigens with mAb to HPV16 E6 suppressed CasKi cervical tumors expressing high levels of E6 (∼600 copies of HPV per cell). However, that study opened the question whether radioimmunotherapy can suppress the growth of cervical tumors with low E6 and E7 expression, such as may be seen in patients. Experimental Design: We evaluated the expression of E6 in patients' tumors and in the siHa cell line expressing low levels of E6 and E7 (1-2 copies of HPV per cell) and found them comparable. We initiated siHa tumors in nude mice, radiolabeled C1P5 mAb to E6 with a beta-emitter 188-Rhenium (188Re) and treated tumor-bearing mice with: (1) 200 μCi 188Re-C1P5 alone; (2) proteasome inhibitor MG132 alone; (3) MG132 followed by 200 μCi 188Re-C1P5; (4) unlabeled C1P5; (5) 200 μCi 188Re-18B7 (isotype-matching control mAb); (6) no treatment. 188Re-C1P5 alone and in combination with MG-132 significantly retarded tumor growth compared to all control groups. Conclusions: Our data demonstrate the possibility to suppress tumor growth by targeting viral antigens even in cervical tumors with low E6 expression and provide additional evidence for the potential usefulness of radioimmunotherapy targeting HPV-related antigens in the clinic.

AB - Purpose: HPV16 is associated with ∼50% of all cervical cancers worldwide. The E6 and E7 genes of oncogenic HPV types, such as HPV16, are necessary for the HPV transforming function and tumorogenesis making them ideal targets for novel treatments. Radioimmunotherapy employs systemically administered radiolabeled monoclonal antibodies (mAbs) that bind to tumor-associated antigens. Previously we demonstrated in mice that radioimmunotherapy targeting viral antigens with mAb to HPV16 E6 suppressed CasKi cervical tumors expressing high levels of E6 (∼600 copies of HPV per cell). However, that study opened the question whether radioimmunotherapy can suppress the growth of cervical tumors with low E6 and E7 expression, such as may be seen in patients. Experimental Design: We evaluated the expression of E6 in patients' tumors and in the siHa cell line expressing low levels of E6 and E7 (1-2 copies of HPV per cell) and found them comparable. We initiated siHa tumors in nude mice, radiolabeled C1P5 mAb to E6 with a beta-emitter 188-Rhenium (188Re) and treated tumor-bearing mice with: (1) 200 μCi 188Re-C1P5 alone; (2) proteasome inhibitor MG132 alone; (3) MG132 followed by 200 μCi 188Re-C1P5; (4) unlabeled C1P5; (5) 200 μCi 188Re-18B7 (isotype-matching control mAb); (6) no treatment. 188Re-C1P5 alone and in combination with MG-132 significantly retarded tumor growth compared to all control groups. Conclusions: Our data demonstrate the possibility to suppress tumor growth by targeting viral antigens even in cervical tumors with low E6 expression and provide additional evidence for the potential usefulness of radioimmunotherapy targeting HPV-related antigens in the clinic.

KW - 188-rhenium

KW - Cervical cancer

KW - E6 oncoprotein

KW - Radioimmunotherapy

KW - Viral antigens

UR - http://www.scopus.com/inward/record.url?scp=78549291460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78549291460&partnerID=8YFLogxK

U2 - 10.4161/cbt.10.10.13322

DO - 10.4161/cbt.10.10.13322

M3 - Article

VL - 10

SP - 1041

EP - 1047

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 10

ER -